Mounjaro®
Starting from £179.99/mo
Start journey Learn moreChest tightness is not listed as a common side effect of Wegovy (semaglutide) in its UK prescribing information, but it is a symptom that deserves a clear answer rather than a quick dismissal. If you have noticed chest tightness while taking Wegovy, the feeling is real — the question is what is likely causing it and when it warrants urgent attention. Semaglutide acts on GLP-1 receptors throughout the body, and its most frequent effects are gastrointestinal; the NHS medicines page for semaglutide lists nausea, vomiting, diarrhoea and constipation as the effects patients most commonly report. Chest-related symptoms sit in a different category, and understanding that distinction matters.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The STEP 1 trial, published in the New England Journal of Medicine, followed 1,961 adults taking semaglutide 2.4 mg weekly for 68 weeks and recorded adverse events in detail. Nausea affected around 44% of participants; chest tightness as an independent symptom was not among the frequently reported findings. That does not mean nobody experiences it (trial populations are monitored but individual experiences vary) but it does mean there is no established signal linking semaglutide directly to chest tightness in the way there is for nausea or reflux.
The NHS semaglutide medicines guide lists the side effects by frequency. Under common effects (affecting more than 1 in 100 people) you find the familiar GI cluster. Chest tightness does not feature in those tiers. What the guidance does flag, appropriately, is that any new chest symptoms alongside shortness of breath, dizziness or pain radiating to the arm require immediate medical attention, not because Wegovy is known to cause heart events, but because those symptoms in any context should never be waited out.
A question our prescribers hear most weeks is whether a tight or heavy feeling across the chest is the medicine or something else entirely. The honest answer is that context matters enormously: when it started, what else was happening at the time, and whether it came with other symptoms.
This is where the evidence becomes practically useful. Semaglutide slows gastric emptying and reduces appetite significantly. Those two effects, while central to how it supports weight loss, can also produce sensations that sit surprisingly high in the chest. Acid reflux and indigestion are listed as common effects of semaglutide, and reflux in particular can produce a burning pressure behind the sternum that many people describe as chest tightness rather than heartburn.
Trapped wind is another factor worth raising here. The relationship between Wegovy and excess gas is well-documented among patients, and gas accumulating in the upper GI tract can cause real pressure and discomfort in the chest and upper abdomen. It tends to ease with movement or passing wind, which helps distinguish it from cardiac-type chest pain. Similarly, nausea severe enough to involve retching can leave the chest muscles sore and tight for hours afterwards.
None of this is trivial, these sensations are uncomfortable and can be alarming. But understanding their likely origin helps you judge how urgently you need to act and what to tell your prescriber when you speak to them.
There are patterns of chest tightness that should prompt a 999 call or an urgent trip to A&E, and Wegovy does not change that calculus. The MHRA's guidance on GLP-1 medicines makes clear that patients should seek help promptly for symptoms that could indicate a serious reaction, and the broader principle (that chest pain with breathing difficulty, sweating, nausea and arm or jaw pain is a medical emergency) applies to everyone, regardless of which medicines they are taking.
The MHRA also flagged in its January 2026 Drug Safety Update on GLP-1 medicines that severe, persistent abdominal pain radiating to the back may indicate acute pancreatitis, which can occasionally be accompanied by chest discomfort. That update, published at yellowcard.mhra.gov.uk, is the right place to report any suspected side effect, including chest symptoms you believe may be linked to your treatment. Reporting takes minutes and helps build the UK safety dataset for these medicines.
If your chest tightness is new, happens consistently around the time of your weekly injection, or has intensified since a dose increase, those are specific details your prescriber needs. You can read more about the broader landscape of chest pain and semaglutide and about what constitutes chest pain on Wegovy in related pages on this site. There is also a broader overview of what Wegovy is and is not known to cause that covers the full side-effect picture in more depth.
If you have experienced chest tightness and are unsure whether to continue, the right move is not to stop unilaterally and not to push on regardless, it is to speak to your prescriber. They can look at the timing, your dose history, and any other symptoms to work out whether what you are experiencing is a recognised GI effect, something unrelated to semaglutide, or a reason to pause and investigate further.
For broader context on how Wegovy works and what it is licensed for in the UK, the Wegovy overview page covers the essentials, and the semaglutide guide goes into more clinical detail. If you are thinking about starting treatment and want to understand the full picture before doing so, speaking to our prescribers is the right next step, they review every consultation personally and can answer questions like this in the context of your own health.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.